The Indian Pharmaceutical Market (IPM) has posted a negative growth of 2.2% for the month of August 2020, after registering a marginal growth of 0.2% for the month of July 2020, due to ongoing COVID crisis.
According to AIOCD AWACS report, the IPM has recorded sales of Rs. 1,42,251 crore for moving annual total (MAT) basis during August 2020. Amongst the top 10 corporates, Mankind exhibited the highest growth of 9.1 per cent, followed by Torrent Pharma at 7.2 per cent. Amongst the 11 to 25 ranked corporates, Aristo exhibited highest growth of 14.3 per cent followed by Glenmark at 13.1 per cent.
Amongst the 26 to 50 ranked corporates, Boehringer Ingelheim registered the highest growth 25.4 per cent followed by JB Chemicals at 15.7 per cent. Amongst the 51 to 75 ranked corporates, Danone registered the highest growth 29.4 per cent and Koye at 14.9 per cent. Amongst the 76 to 100 ranked corporates, Reckitt Benckiser exhibited the highest growth at 30.1 per cent, followed by Llyod Hc at 28.2 per cent.
Cardiac has stabilized, but with lower growth of 11.5% as compared to 13.1% in July 2020, while on MAT basis, growth is 11.6%. Anti-diabetic registered growth of 1.6 % as compared to 5.9% in July 2020, while on MAT basis growth is 8.4%.
The respiratory medicines growth slumps to -12.4 % as compared to -2% in July 2020, while on MAT basis growth is 7.9%.
Post unlockdown since June 2020, the struggle for anti-infectives -10.2 % in July 20 continues negative trend -11 % in August 2020, while on MAT basis growth is 0.1%.
Associated therapy like gastro exhibits negative growth of -2.4 % in July continues to further bleed at -3.1% in August 2020, while on MAT basis growth is 1.7%.
Vitamins have bounced back has growth of 5.5% in July and continues growth trend to 6.2% in August 2020 , while on MAT basis growth is 4.4%. Pain and analgesics were struggling at -6.7% in July 2020 and continues down trend -9.8 % in August 20, while on MAT basis growth is 0.4%.
Source : 1